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Idiopathic collapsing focal segmental glomerulosclerosis: A clinico-
pathologic study. A review of all native kidney biopsies at our center from
1974 to 1993 identified 43 cases of idiopathic focal segmental glomcrulo-
sclerosis (FSGS) with predominantly collapsing features and lacking
evidence of HIV-1 infection or intravenous drug use. No case was
identified before 1979 and the incidence of this entity has progressively
increased over the past two decades. Compared to 50 age-matched
controls of idiopathic FSGS with typical perihilar scars, the group of
idiopathic collapsing FSGS displayed black racial predominance, a higher
serum creatinine and more severe features of nephrotic syndrome at
biopsy. Morphologic features of visceral epithelial cell hypertrophy and
hyperplasia, tubular mierocysts, tubular epithelial degenerative and regen-
erative features and interstitial edema were more prevalent and severe in
collapsing FSGS. Median time to ESRD was rapid in collapsing FSGS
versus controls (13.0 months vs. 62.5 months, P < 0.05). Correlates of
progression to ESRD included a higher initial serum creatinine and failure
to undergo remission of proteinuria. Both glomerulosclerosis and certain
features of tubular damage were independent predictors of the level of
renal function at time of biopsy, hut not of the rate of progression of renal
insufficiency. Although three patients had partial or complete spontaneous
remissions, none of 26 patients treated with steroids alone responded.
Idiopathic collapsing FSGS is a variant of FSGS with increasing incidence,
distinct clinicopathologic features, black racial predominance, a rapidly
progressive course and relative steroid resistance.
Focal segmental glomerulosclerosis (FSGS) is a common pat-
tern of glomerular injury comprising up to 20% of all cases of
idiopathic nephrotic syndrome in adults [1]. Several independent
investigators have documented the increasing frequency of both
idiopathic and secondary forms of FSGS in renal biopsies in
recent years [2, 3]. Although both the course of idiopathic FSGS
and the response to immunosuppressive therapy may vary, many
patients progress to renal failure. In an attempt to predict the
prognosis and account for the heterogeneous course of patients
with FSGS, a number of histopathologic patterns of FSGS have
been defined including FSGS with diffuse mesangial hypereellu-
larity, a cellular variant, and the glomerular "tip lesion" [4—7]. The
prognostic importance of these histologic subsets remains contro-
versial (81. In 1986, Weiss and co-workers described a small group
of patients with a rapidly progressive form of FSGS characterized
by unusual histologic features of focal segmental and global
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"collapse" of the glomerular capillary walls accompanied by
marked visceral cell hypertrophy [9]. All six patients had very
heavy proteinuria and a rapid course to renal failure over 0.5 to 48
months. Only one of these patients was later found to have the
Acquired Immunodeficiency Syndrome (AIDS), although data
regarding HIV-1 infection were not reported for the other
patients. Subsequently, Detwiler et al reported sixteen patients
with a similar "collapsing" pattern of idiopathic FSGS in the
absence of evidence of HIV-1 infection or intravenous drug use
[10]. Their patients had similar clinical features to those described
by Weiss et al with more rapid progression to renal failure than
seen in other patients with FSGS. These reports suggest a distinct
subset of idiopathic FSGS with unusually rapid progression to
renal failure.
At Columbia-Presbyterian Medical Center, we have also noted
an increasing incidence of all eases of FSGS among biopsies
submitted to our renal pathology division over the last two
decades [31. There has also been a striking increase in idiopathic
FSGS with collapsing morphologic features among patients lack-
ing clinical or serologic evidence of HIV-1 infection or risk factors
for HIV-1 infection. A retrospective review of 240 cases of
idiopathic FSGS accessioned by the Columbia-Presbyterian Ne-
phropathology Laboratory over the past 20 years identified our
first case of idiopathic collapsing FSGS in 1979 [3]. Since that time
the incidence of this entity has increased from 11% of all
idiopathic FSGS from 1979 to 1985, to 20% of all idiopathic FSGS
from 1986 to 1989, to 24% from 1990 to 1993 [3].
To better characterize the clinical and morphologic features of
this variant of FSGS and to determine which epidemiologic,
clinical and histologic features may he of prognostic significance,
we performed a detailed evaluation of 43 patients with idiopathic
collapsing FSGS. Their features were compared to 50 age-
matched controls with the classic histologic form of idiopathic
FSGS.
Methods
All biopsies of idiopathic FSGS accessioned by the Renal
Pathology Laboratory at Columbia-Presbyterian Medical Center
from 1974 10 1993 were re-reviewed for proper classification.
Among 4073 native kidney biopsies, there were 394 cases of
FSGS, of which 240 were idiopathic FSGS. Of these, 43 cases
(18%) manifested predominantly collapsing features and lacked
evidence of HIV-1 infection or intravenous drug use. Morpho-
logic criteria for inclusion were the demonstration in histologic
sections of focal glomerulosclerosis characterized by segmental or
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Fig. 1. There is global collapse of the glomerular
capillaries without increased intracapillaiy matrix.
Viscera! epithe!ia! ce!!s are markedly
hypertrophicd. (Jones methenamine silver,
x500).
global wrinkling and "collapse" of the glomerular capillary walls
with prominent hypertrophy and hyperplasia of the overlying
visceral epithelial cells, often accompanied by intracytoplasmic
protein resorption droplets, as illustrated in Figure 1. Biopsies
with any glomeruli demonstrating global collapse and/or over 20%
of glomeruli with segmental collapse qualified as meeting patho-
logic entry criteria for collapsing FSGS. The number of glomeruli
exhibiting collapsing features and the degree of tubulointerstitial
damage were variable.
None of the 43 cases had any known risk factor for HIV-1
exposure and none developed signs or symptoms of HIV-1
infection during the follow-up period which ranged up to 135
months (mean 32.2 months). In 33 cases, serologic testing for
antibody to HIV-1 by ELISA was available and was negative in
every case. No patient had clinical evidence of any secondary
cause of FSGS such as heroin abuse, reflux nephropathy, sickle
cell disease, obesity or reduced renal mass.
Case histories were reviewed for demographic and clinical data
including presenting features at the time of biopsy, course,
treatment and outcome. Renal biopsies were processed according
to standard techniques for light microscopy, fluorescence micros-
copy and electron microscopy. At least 12 histologic levels were
stained with hematoxylin-eosin, periodic acid-Schiff (PAS), Mas-
son's trichrome and Jones methenamine-silver stains. Histologic
features were graded by calculating the percentage of glomeruli
exhibiting a particular histologic finding (global or segmental
collapse, or global or segmental glomerulosclerosis) and by semi-
quantitative analysis (using a scale of 0 to 3+) for the following
features: visceral epithelial cell hypertrophy and hyperplasia,
tubular microcysts, tubular epithe!ial degenerative and regenera-
tive changes, tubular atrophy, interstitial edema, inflammation
and fibrosis. In the case of tuhulointerstitial features, these were
accorded 0 for absent, 1 for < 20%, 2 for 20 to 50% and 3
for > 50% of the biopsy surface affected.
Partial remission of proteinuria was defined as a reduction in
proteinuria to less than 2 grams daily and a full remission as less
than 1 gram daily. End-stage renal disease (ESRD) was defined as
the time point at which renal replacement therapy was initiated.
All clinical and pathologic features were compared to those of a
control group of 50 patients with idiopathic FSGS and classic
biopsy features of FSGS defined as segmental scars with increased
matrix and variable hyalinosis without global glomerular base-
ment membrane collapse. Controls were matched for age and year
of renal biopsy.
Statistical analysis was performed using standard I-testing,
X2-analysis, Wilcoxon rank sum analysis, linear regression analy-
sis, life table analysis and one-way ANOVA, as appropriate.
Statistical significance was assumed at P value < 0.05, with
correction for multiple comparisons by the method of Bonferroni.
Rate of progression of renal insufficiency was defined as the
slope of the best fit-linear regression analysis of the inverse
creatinine-time curve (using 4 or more time points for each
patient starting from the time of biopsy). A multiple regression
analysis was performed for predictors/correlates of: (1) rate of
progression of renal insufficiency, and (2) serum creatinine at
biopsy, for both the collapsing and control FSGS groups. Demo-
graphic (age, race/ethnicity, gender), clinical (degree of protein-
uria, hypertension, remission of proteinuria) and all histologic
variables were added to the model. Variables which appeared to
correlate best were carried through succeeding models until the
best correlation could be obtained.
Results
Clinical features at presentation
The mean age of patients with idiopathic collapsing FSGS at
the time of renal biopsy was 32.2 years (range of 1.5 to 72 years).
There were 10 pediatric patients (23%) of which only four (9%)
were 12 years or younger, and only seven (16%) were over 50
years old. The male-to-female ratio of 1.38 in the collapsing FSGS
group was not significantly different from controls (Table 1).
There was a strong and significant black racial predominance
(61%) among the collapsing FSGS patients compared to controls
(22%; P < 0.025).
Thirty-five of the 43 cases (82%) presented with the nephrotic
syndrome, 4 (9%) with the nephrotic syndrome and uremia and 4
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Collapsing FSGS(N = 43)
Control FSGS
(N = 50)
P
value
Age years 32.2 32.8 NS
mean (range) (1.5—72) (1—67)
Race/ethnicity
White 17% 54%
Black 61% 22% <0.025
Hispanic 22% 24%
Gender % male 58% 50% NS
Collapsing FSGS(N = 43)
Control FSGS
(N = 50)
P
value
Creatinine mg% 4.2 (0.8—24) 2.0 (0.4—14) NS
% Creatinine < 2.0 54% 76%
Time to biopsy months 7.9 (1—72) 48.6 (1—360) <0.025
uv rotoja g/day
UVpr0tcjr, > 3.0
Uprotain/Ucraati,rina
10.2 (2.2—36.6)
91%
11.0(1.6—44.4)
6.9 (0.4—24.4)
75%
5.4 (1.0—25.9)
NS
NS
% Up0/U > 3.0 87% 58%
Albumin g/dl 2.4 (1.0—4.1) 2.9 (1.0—4.5) NS
% Albumin < 3.5 91% 53%
Cholesterol mg/dl 404 (154—993) 335 (165—873) NS
% Chol. > 240 74% 65%
% Chol. > 300 65% 44%
Nephrotic syndrome 91% 60% <0.025
Hypertension 65% 56% NS
Data are: mean (range). Abbreviations are: UVprn, 24-hour urinary
protein excretion; UO /Uc (or Uprot/Ucr), spot urinary protein-
to-creatinine ratio.
(9%) with uremia alone. One patient had a history of Sjogren's
syndrome and one had serologic evidence of systemic lupus
erythematosus (ANA positive at 1:320, elevated double-stranded
anti-DNA antibody titer and reduced serum complement) without
clinical features fulfilling American Rheumatology Association
(ARA) criteria for the diagnosis of SLE. Only four patients (9%)
had constitutional symptoms or signs at presentation not ex-
plained by nephrotic syndrome or uremia, including: (1) one
patient with fever, headache, nonspecific rash, myalgias, anorexia
and weight loss; (2) one patient with fever, alopecia and abnormal
liver function tests; (3) one patient with non-infectious diarrhea
and weight loss; and (4) one patient with a non-bacterial pharyn-
gitis. No patients were receiving potentially ncphrotoxic medica-
tions at the time of disease onset.
When clinical features at the time of biopsy were compared
(Table 2), patients with collapsing FSGS had a higher serum
creatinine (4.2 vs. 2.0 mg/dl) despite a much shorter period of time
from onset of renal disease to biopsy (7.9 vs. 48.6 months, P <
0.025), suggestive of a more rapidly progressive form of renal
disease and not a delay in recognition. Ninety-one percent of
patients with collapsing FSGS manifested nephrotic syndrome
compared to 60% of controls (P < 0.025). All markers of the
nephrotic syndrome were more prevalent and severe in the
collapsing FSGS group, including more severe proteinuria (10.2
vs. 6.9 g/day), a lower serum albumin (2.4 vs. 2.9 g/dl) and edema
(74% vs. 50%) though none reached statistical significance. There
was no difference in serum cholesterol levels (404 mg/dl vs. 335
Collapsing Control
FSGS FSGS P
(N 43) (N = 50) value
Of all glomeruli
Global collapse %
Global + segmental collapse %
Global sclerosis %
Global + segmental sclerosis %
2+ Or greater on semiquantitative
analysis
Glomerulomegaly 5% 10% NS"
VEC hypertrophy 67% 18% <0.025k
VEC hyperplasia 84% 38% <0.025k'
Abbreviation is VEC, visceral epithelial cell. The semiquantitative scale
is 0 to 3+.
a by Wilcoxon Rank Sum Analysis
h by x2 analysis
18% 0% <0.025°
52% 1.3% <0.025°
17% 18% NS
23% 43% <0.025°
mg/dl, P = NS) or the prevalence of hypertension (65% vs. 56%,P = NS) in collapsing FSGS versus classic FSGS controls.
Renal biopsy findings
The defining histologic feature of this form of FSGS was a
global or segmental "collapse" of the glomerular capillary walls
characterized by a distinctive wrinkling and retraction of the
glomerular basement membranes resulting in obliteration of the
glomerular capillary lumen with marked visceral cell hypertrophy
and hyperplasia (Fig. 1). This process was best appreciated in PAS
or silver stained sections and was sometimes associated with loss
of endothelial and mesangial cells in the involved segments.
Typically, there was little or no increase in endocapillary or
mesangial matrix and both hyalinosis and endocapillary foam cells
were rarely if ever identified. Glomerular involvement by collapse
could be either segmental or global without obvious predilection
for the perihilar region. A mean 18% of glomeruli (range 0 to
55%) exhibited global collapse and a mean 34% (range 0 to 92%)
segmental collapse, so that a mean 52% (range 6 to 100%) of all
glomeruli demonstrated collapsing features (Table 3). The vis-
ceral epithelial cells were often so hypertrophied as to form
pseudo-crescents which could be differentiated from true cres-
cents by their lack of spindled cellular morphology, intercellular
matrix or attachment to Bowman's capsule (Fig. 2). These visceral
epithelial cells often demonstrated extremely swollen cytoplasm
containing hyaline protein resorption droplets that stained pink
with the PAS stain and red with the trichrome stain. Their nuclei
were typically enlarged with a vesicular chromatin pattern, in-
creased number of nucleoli and focal mitotic figures (Fig. 3).
Synechiae were rarely observed between the tuft and Bowman's
capsule. Glomeruli unaffected by tuft collapse either appeared
histologically normal (except for some visceral cell swelling) or
demonstrated more classic lesions of segmental or global sclerosis
characterized by increased matrix, hyalinosis and Bowman's cap-
sular adhesions. Glomerular hypertrophy was not recognized as a
feature of this condition.
A characteristic finding in this variant of FSGS was the pres-
ence of severe tuhulointerstitial disease that often appeared out of
proportion to the degree of glomerulosclerosis (Table 4). In
addition to tubular atrophy, interstitial fibrosis, edema and inflam-
mation there were frequent tubular degenerative and regenerative
changes. The latter included simplification of the epithelial lining
Table 1. Demographics of idiopathic collapsing FSGS Table 3. Histology of idiopathic collapsing FSGS—Glomerular
Table 2. Clinical features at biopsy of idiopathic collapsing FSGS
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Fig. 2. Glomerular capillaries are occluded by
collapse of the glomerular basement membranes.
Visceral epithelial cells are hypercellular,
forming pseudocrescents. Podocytes contain
many intracytoplasmic vacuoles and protein
resorption droplets. (Jones methenamine silver,
x500).
Fig. 3. With the hematoxylin-eosin stain, the
glomerulus appears hypercellular due to severe
visceral cell proliferation. One visceral epithelial
cell is in mitosis (arrow) (Hematoxylin-eosin,
><500).
of proximal tubules, enlarged vesicular nuclei with frequent
nucleoli and mitoscs, focal apoptosis and shedding of desqua-
mated epithelial cells into the tubular lumen (Fig. 4). Eighteen of
43 cases (42%) demonstrated tubular microcysts, which contained
loose proteinaceous casts (Fig. 5). Arteriosclerosis was present in
27 of 43 cases (63%).
By immunofluorescence microscopy, there was focal segmental
or global staining of the glomerular tuft with antisera to 1gM
(95%), C3 (93%) and C1 (49%) (Fig. 6). Visceral epithelial cell
protein resorption droplets often stained for IgG, lgA and
albumin, with similar staining in the tubular epithelial protein
droplets (Fig. 7).
Electron microscopy disclosed prominent wrinkling and gener-
ally little or no thickening of glomerular basement membranes in
the affected lobules. The overlying visceral cells were generally
markedly hypertrophied and capped with complete effacement of
foot processes, focal detachment and increased number of protein
Table 4. Histology of idiopathic collapsing FSGS—Tubulointerstitial
Collapsing FSGS Control FSGS P
________________________
(N = 43) (N = 50) value
2+ Or greater on semiquantitative analysis
Tubular microcysts 12%
Tubular degeneration 14%
Tubular regeneration 21 %
Tubular atrophy 51%
Interstitial edema 26%
Interstitial inflammation 44%
Interstitial fibrosis 62%
The semiquantitativc scale is 0 to 3+. All comparisons arc by g
analysis.
resorption droplets, clear transport vesicles and abundant rough
endoplasmic reticulum (Figs. 8 and 9). Adjacent glomerular
capillaries unaffected by collapse were notable for extensive
0%
0%
4%
32%
0%
18%
30%
<0.025
<0.025
<0.025
NS
<0.025
NS
NS
Fig. 4. The tubules show widespread epithelial
simplification with regenerative nuclear atypia and
focal mitotic figures (arrow). There is interstitial
edema and inflammation (Hematoxylin-eosin,
><500).
(mean 80%) effacement of foot processes. In contrast to their
frequent occurrence in biopsies of HTV-i-infected patients, tubu-
lo-reticular inclusions were found within the cytoplasm of a single
glomerular cndothclial cell in only 2 of the 43 cases.
Comparative morphologic data
Comparative morphologic data between renal biopsies of pa-
tients with idiopathic collapsing FSGS and idiopathic classic
FSGS controls are presented in Tables 3 and 4. For the collapsing
group, a mean of over half (52%) of glomeruli had either global
or segmental collapse with nearly one-fifth (mean 18%) exhibiting
global collapsing features. Conventional lesions of segmental
sclerosis defined as discrete foci of increased intracellular matrix,
with or without hyalinosis, and Bowman's capsular adhesion were
identified in only 5% (mean) of glomeruli. This is in contrast to
25% of glomeruli demonstrating classic lesions of segmental
glomeruloscierosis among controls (P < 0.025). There was signif-
icantly greater visceral cell hypertrophy and hyperplasia among
the collapsing group (both P < 0.025). All histologic markers of
tubulointerstitial injury were greater in collapsing FSGS than
control FSGS biopsies, and these reached statistical significance
for the parameters of tubular microcysts, tubular degenerative
and regenerative changes and interstitial edema, but not tubular
atrophy, interstitial inflammation or fibrosis.
Treatment and outcome
Of the 43 patients with collapsing FSGS, 26 (60%) received
immunosuppressive treatment for their renal disease (Table 5).
These 26 patients were all first given a trial of prednisone. Ten
pediatric cases received prednisone 60 to 80 mg/day. Of the 16
adult patients, half received prednisone 1 mg/kg/day and the other
half received 2 mg/kg on alternate days. All received at least a
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Fig. 5. Low power view showing global
glomerulosclerosis and global glomerular collapse.
There are focal tubular microcysts as well as
patchy tubular atrophy and interstitial fibrosis
(Jones methenamine silver, >< 125).
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Fig. 6. By fluorescence microscopy there is global
staining of the collapsed glomerular lobules with
antisera to 1gM (X500).
Fig. 7. Visceral epithelial cells contain
intracytoplasmic protein resorption droplets which
are highlighted with antisera to albumin (X500).
two-month trial of steroid therapy but only five patients (3 adults
on daily prednisone and 2 adults on an alternate day regimen)
received at least a six-month course of corticosteroids. Six patients
also received cyclophosphamide (3 pediatric and 2 adult cases
who received oral cyclophosphamide for 5 to 12 weeks and 1 adult
case who received a six-month course of intravenous pulse
cyclophosphamide of I g/M2/month). Three patients received a
trial of cyclosporine A (4 to 5 mg/kg/day for 8 to 26 weeks). There
were no complete or partial remissions of proteinuria in the 26
steroid-treated patients. One partial remission was obtained
among the 6 cyclophosphamide-treated patients (17%), and 2
remissions (one complete and one partial) among the three
cyclosporine A-treated patients. Three untreated patients experi-
enced a spontaneous remission of proteinuria (2 full, 1 partial).
Therefore, there was a total 14% remission rate among the
collapsing FSGS patients, compared to a 36% remission rate (16
full, 2 partial) among the control FSGS group (Table 5). These
remissions in the collapsing FSGS group have been followed for a
mean of 53 months (range 21 to 135 months). One patient has
relapsed and progressed to ESRD. There was no difference in
steroid treatment rate between the collapsing FSGS group and
the historical control FSGS group (60% vs. 78%, P = NS),
although the collapsing FSGS were much less likely to have
received a full six-month trial of prednisone (5 out of 26 or 19%
vs. 19 out of 39 or 49%). There was no difference in the treatment
rates with cyclophosphamide (14% vs. 20%, P = NS); however,
the collapsing FSGS group were less likely to be treated with
cyclosporine A (7% vs. 24%), perhaps as a reflection of the more
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advanced renal insufficiency at biopsy in the collapsing FSGS
group.
Patients with idiopathic collapsing FSGS were followed for a
mean of 32.2 months (range 6 to 135 months). At last follow-up,
51% of these patients reached ES RD. By life table analysis, the
median renal survival measured from the time of biopsy to ESRD
was significantly shorter in the collapsing versus the control group
(13.0 months vs. 62.5 months, P < 0.05, Table 6 and Fig. 10).
Three patients underwent a second renal biopsy. All three dem-
onstrated a progression from a predominantly focal and segmen-
tal to a more diffuse and global glomerular collapse on repeat
biopsy. Among patients with collapsing FSGS, 7received a renal
transplant, including one living-related and 6 cadaveric grafts.
Two grafts were lost to rejection and none developed evidence of
recurrent disease.
Evaluation of the demographic and clinical features which
might he predictive of outcome in idiopathic collapsing FSGS was
first analyzed by dichotomizing patients using ESRD as end-point.
Comparative analysis of those who progressed to ESRD versus
those who did not progress to ESRD uncovered no significant
differences with respect to age, race or gender (data not shown).
Clinical predictors of outcome included the serum creatinine at
biopsy (I' < 0.05) and lack of remission of proteinuria (P < 0.025).
However, there was no correlation between outcome and the
severity of protcinuria or other features of the nephrotic syn-
drome (Table 7).
There were no histologic features which were found to distin-
guish those with rapid progression to ESRD from those with no or
slow progression. Of note, the percentage of glomeruli with
segmental or global collapse, severity of visceral cell hypertrophy
or hyperplasia, tubular microcysts, degenerative or regenerative
tubular changes and interstitial edema, inflammation or fibrosis
did not correlate with outcome (data not shown).
Predictors of progression were also analyzed using the rate of
decline of renal function expressed as the slope of the best
fit-linear regression model of the inverse creatinine-versus-time
curve, calculated from the time of biopsy to either ESRD or last
available follow-up. The rate of progression did not correlate with
the severity of the nephrotic syndrome as defined by the level of
urinary protein excretion or serum albumin for the collapsing
FSGS group, but did correlate for the control FSGS group (Table
8). The rate of progression in the collapsing FSGS group corre-
lated highly with the severity of tubular degenerative and regen-
erative changes by ANOVA (P < 0.02, data not shown), but not
with any other tubulointerstitial parameter nor with the degree of
glomerular collapse or sclerosis.
In the collapsing FSGS patients, the serum creatinine at biopsy
correlated weakly but significantly with the percent of globally
sclerotic glomeruli (r = 0.51, P < 0.02) but no other histologic
feature. This is in contrast to the control FSGS group for which
multiple significant histologic correlations were found with serum
creatinine, including the percent of sclerotic glomcruli, degree of
tubular regenerative changes and interstitial inflammation (all
P < 0.02, data not shown).
By multiple regression analysis, the serum creatinine at biopsy
in collapsing FSGS patients correlated significantly with male
gender (higher creatinines), global glomerulosclcrosis, tubular
regenerative features and tubular atrophy but not race, degree
(percent) of glomerular collapse or interstitial disease (Table 9).
Similarly, global glomerulosclerosis and tubular regenerative fea-
tures (the latter rare in control FSGS) were significant correlates
of the serum creatinine at biopsy in control FSGS (Table 9). By
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Fig. 8. Electron micrograph showing early
collapse with segmental wrinkling and pleating of
the glomerular basement membrane. There is
extensive foot process fusion of the overlying
podocyte. There are no endothelial tubulo-
reticular inclusions (uranyl acetate, lead citrate,
x3500).
(4)
'J.2'.
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Fig. 9. Electron micrograph illustrating an advanced stage of glomerular basement membrane collapse with obliteration of the capillaiy lumen and
detachment and hypertrophy of the visceral epithelial cells forming a cellular cap (uranyl acetate, lead citrate, X2500).
Table 5. Treatment response of idiopathic collapsing FSGS
Full remission
<1 g/day
Partial remission
< 2g/day
Spontaneous 2/43 (5%) 1/43 (2%)
Steroids 0/26 (0%) 0/26 (0%)
Cytotoxics 0/6 (0%) 1/6 (17%)
Cyclosporine A 1/3 (33%) 1/2 (33%)
Cytotoxics are principally oral cyclophosphamide.
multiple regression analysis (Table 10), including all demo-
graphic, clinical and histologic features, the rate of progression of
renal dysfunction in collapsing FSGS correlated best only with
male gender as a predictor of faster progression (P = 0.076). In
comparison, the rate of progression in control FSGS correlated
significantly with hypoalbuminemia, segmental collapse of gb-
meruli (by definition, there was no global glomerular collapse in
control FSGS) and total glomerulosclerosis (Table 10).
Discussion
Focal segmental glomerulosclerosis (FSGS) is a heterogenous
group of disorders with respect to etiology, morphology, clinical
course and response to treatment [8—li]. Primary or idiopathic
FSGS must be differentiated from secondary forms of FSGS
including those associated with remnant kidneys and hyperfiltra-
tion, sickle cell disease, obesity, heroin nephropathy and other
Table 6. Outcome of idiopathic collapsing FSGS
Collapsing
FSGS
(N = 43)
Control
FSGS
(N = 50)
P
value
ESRD (over time of follow-up) 51% 42% NS
Follow-up time months 32.2 61.4 NS"
Median renal
Survival time months 13.0 62.5 <0.05'
(from biopsy)
U By x2 analysis
By unpaired t testing
By lifc table analysis
disorders [8, 11—17]. Within the last decade, HIV-associatecl
nephropathy (l-IIVAN), an entirely new Firm of secondary FSGS
with a unique clinical picture, morphology and a rapid course to
renal failure has been defined [18, 19]. Most recently, a number of
reports have described small series of patients without evidence of
HIV-l infection but with a similar collapsing variant of FSGS anti
a rapid progression to ESRD [9, 10]. Weiss et al in 1986 first
described six patients with a new gbomerulopathy characterized by
prominent gbomerular tuft collapse, heavy proteinuria and the
rapid development of ESRD [9]. In the three year follow-up, only
one of these patients developed overt AIDS. More recently,
Detwiler et al reported 16 patients with collapsing FSGS and no
serologic or clinical evidence of concurrent HIV-1 infection [10].
100k
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Table 8. Correlations of rate of progression in idiopathic collapsing
FSGS (from time of hiopsy)—clinical features
____________
Collapsing FSGS Control FSGS
Rate of progression (= slope of inverse creatinine-time curve)
vs. UVpr,,tj r = 0.23, P = NS r = 0.32, P = NS
vs. Upr,ti,,/Ucrat,j,. r = 0.25, P = NS r = 0.72, P < 0.02
vs. serum albumin r = 0.32, P = NS r = 0.53, P < 0.02
UVpro, is 24-hour urinary protein excretion; Uproc is the
spot urinary protein-to-creatinine ratio. By linear regression analysis.
Table 9. Multivariate analysis of predictors of serum creatinine at time
of biopsy
Paramete
estimate
r Standard
error
P
value
Collapsing FSGS (,2 = 0.75) F = 10.79 0.001
Male gender —2.15 0.87 0.0203
% Global glomerulosclerosis +0.08 0.03 0.0 144
Tubular regeneration +1.30 0.56 0.0295
Tubular atrophy +1.44 0.51 0.0095
Control FSGS (r2 = 0.64) F = 40.59 0.0001
% Global glomerulosclerosis +0.06 0.01 0.0001
Tubular regeneration +3.28 0.71 0.0001
Fig. 10. Life table analysis of renal survival (free of ESRD) in idiopathic
collapsing versus control FSGS (X2 analysis; P < 0.05).
Table 7. Predictors of progression in idiopathic collapsing FSGS
(clinical features at biopsy)
ESRD Not ESRD P
(N = 22) (N = 14) value
Serum creatinine mg/dl 6.7 1.4 <0.05
Time to biopsy months 9.5 8.6 NS
UVprj, glday 9.4 9.7 NS
Upr,t,j,,/Ucr=ti,i,,c 9.4 12.2 NS
Serum albumin g/dl 2.5 2.4 NS
Serum cholesterol mg/dl 386 417 NS
Hypertension 82% 43% NS
Remission of proteinuria 0% 43% <0.025
These patients manifested heavy proteinuria (mean of over 13
gms daily) and a rapid progression to renal failure. These 16
patients were culled from a total of 849 biopsies performed from
1988 to 1990 by the North Carolina Collaborative Glomerular
Study Group. Both reports describe idiopathic collapsing FSGS as
a newly recognized glomerulopathy at their respective centers.
The current study is the largest clinicopathologic analysis of this
recently identified subgroup of FSGS. In reviewing all 240 biop-
sies with a diagnosis of idiopathic FSGS accessioned at Columbia-
Presbyterian Medical Center from the years 1974 to 1993, no
biopsy with histologic features similar to collapsing FSGS was
found prior to 1979 [3]. Since then, both the absolute number and
relative incidence of collapsing FSGS has progressively increased
through the 1980s and into the 1990s [3j. In the 1990s, collapsing
FSGS comprised 24% of all idiopathic FSGS in our series [3].
Parameter St
estimate
andard
error
P
value
Collapsing FSGS (,2 = 0.09) F = 3.43 0.076
Male gender
Control FSGS (r2 = 0.46)
+23.46
F = 12.69
12.66 0.076
0.0001
Serum albumin +8.55 2.14 0.0003
% Segmental collapse —2.14 0.55 0.0004
in glomeruli
% Total glomerulosclerosis —0.26 0.09 0.0042
(global + segmental)
Although we were unable to document collapsing FSGS in our
FSGS biopsies prior to 1979, the number of FSGS biopsies
received from 1974 to 1979 was relatively small and may have
been subject to sampling bias. Several early reports of FSGS
describe visceral cell hyperplasia and retraction of the glomerular
basement membrane [20 —221 and thus is it likely that examples of
collapsing FSGS existed prior to 1980, although the significance of
these morphologic features was not widely recognized. It is also
possible that under-recognition of collapsing FSGS as a manifes-
tation of idiopathic FSGS prior to 1980 accounts in part for its low
prevalence in that era. However, it is likely that the continued
increase in the observed frequency of this lesion from 1979 to the
present reflects a true change in disease incidence since this rising
trend has been sustained over two decades in a large biopsy
population with standardized, consistent renal biopsy interpreta-
tion.
Idiopathic collapsing FSGS is defined by its histopathologic
features. Both Weiss and Detwiler's series describe the biopsies of
their patients as manifesting prominent "collapse" of the glomer-
ular capillaries [9, 10]. In Weiss' series collapse was focal,
Table 10. Multivariate analysis of predictors of progression (dependent
variable — slope of the inverse creatinine-time curve)
UV,,,,, is 24-hour urinary protein excretion; Up,,j,/Ucrci,in. is the
spot urinary protein-to-creatinine ratio.
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involving from 25 to 50% of all glomeruli, and varied from
segmental to global in distribution. Repeat biopsies in two
patients showed global collapse of all glomeruli. Detwiler's pa-
tients displayed segmental or global collapse in 8 to 92% of the
glomeruli of each biopsy. Our patients also manifested prominent
segmental and global glomerular tuft collapse involving on aver-
age more than 50% of glomeruli. This is in contrast to age-
matched controls with idiopathic FSGS who manifested glomer-
ular scars consisting of increased inframembranous matrix with
frequent hyalinosis and capsular adhesions. All histologic markers
of tubulointerstitial damage were greater in collapsing FSGS
group. The previously reported series also described significant
tubulointerstitial damage with interstitial fibrosis, tubular atrophy,
tubular dilation with cast formation, and mononuclear infiltration
of the interstitium [9, 10].
There is considerable confusion surrounding the definition of
collapsing FSGS and its relationship to "cellular FSGS" as defined
in 1985 by Schwartz and Lewis [5]. While collapsing FSGS can be
considered a particular subtype of cellular lesion, not all cellular
lesions are necessarily collapsing. According to the definition
proposed by Schwartz [5], cellular lesions of FSGS are character-
ized by visceral cell "reactive and proliferative changes" whether
overlying capillaries with minimal histologic abnormalities, hyper-
cellular glomerular capillary segments, segmental scars or col-
lapsed capillaries with wrinkled basement membrane. We reserve
the term collapsing FSGS for the latter situation, in which there is
acute retraction (that is, "collapse") of the glomerular basement
membrane without endocapillary hypercellularity and accompa-
nied by visceral cell hypertrophy and hyperplasia. This is to he
distinguished from examples of cellular FSGS in which there is
endocapillary hypercellularity (including proliferation of endothe-
hal cells, foam cells, infiltrating leukocytes and karyorrhectic
debris) as well as extracapillary (that is, visceral cell) proliferation,
mimicking a proliferative glomerulonephritis. Extracapillary hy-
percellularity characterizes both these forms, but only the collaps-
ing lesion has glomerular basement membrane wrinkling and
retraction. In short, we prefer to distinguish two subtypes of
cellular FSGS as defined by Schwartz, one a collapsing form
without endocapillary hypercellularity and the other a non-col-
lapsing form with endocapillary hypercellularity, both of which
share the features of visceral cell proliferation and reactivity.
Clearly, there is significant overlap in the histologic features of
FSGS in the cellular, collapsing and classic subgroups. Within our
control group with typical perihilar expansile scars, rare glomeruli
with segmental collapsing features were observed in 5 of 50 cases,
affecting less than 20% of glomeruli. Similarly, in the collapsing
group, glomeruli with classic segmental scars were often observed
side by side with collapsed glomeruli. These observations rein-
force our opinion that collapsing glomerulopathy represents one
possible morphologic expression of severe glomerular injury
within the increasingly broad pathologic spectrum of FSGS. Thus,
we favor that collapsing glomerulopathy constitutes a histologic
variant of FSGS rather than a separate or distinct disease entity.
An analogy can be drawn to HI V-associated nephropathy where
collapsing lesions and perihilar scars often co-exist in a given
biopsy, but the prevalence of collapsing lesions exceeds that
observed in series of idiopathic FSGS and correlates with the
more accelerated course to renal failure.
Our series of idiopathic collapsing FSGS exhibited a strong
black racial predominance of 61% versus 22% in controls. This
racial predilection has been noted in both previous smaller series
of collapsing FSGS patients. Indeed, all the patients in Weiss's
report and over 80% of those reported by Detwiler et al were
black [9, 10]. The disease is not, however, limited to blacks and
appears akin to other sclerosing glomerulopathies such as heroin-
associated nephropathy and HIVAN, both of which have a strong
black racial predominance [23, 24]. Whether the racial predilec-
tion is related to HLA differences, altered production and mod-
ulation of sclerosing cytokines such as TGF-p or other growth
factors, a tendency towards more severe or poorly controlled
hypertension or other genetic, or environmental factors cannot be
determined from our study [25—28]. Of interest, among our
patients with idiopathic collapsing FSGS, blacks did not have a
worse course than non-blacks (data not shown), implying that
these predisposing factors may play a greater role in initiating the
collapsing pattern of FSGS than in determining its ultimate
progression and outcome.
Heavy proteinuria and the nephrotic syndrome are a prominent
clinical feature of idiopathic collapsing FSGS. The patients in
Weiss's series all had between 10 and 30 grams of proteinuria
daily, while 69% of the patients reported by Detwiler had over 10
grams proteinuria per day [9, 10]. In our series, as well, the mean
level of proteinuria was higher (10.2 vs. 6.9 g/day) and the
percentage of patients with severe proteinuria, defined as 10 g or
more daily or a spot urinary protein-to-creatinine ratio of 10 or
more, was greater in collapsing FSGS (16 of 43 cases or 37%) than
in controls (12 of 50 cases or 24%). Several other prominent
clinical features of collapsing FSGS, including greater hypoalbu-
minemia, hypercholesterolemia and prevalence of edema, are
probably related to the greater severity of the protein loss. It is not
known whether the increased proteinuria in collapsing FSGS is
not only a manifestation of more severe glomerular injury but also
directly contributes to the progressive glomerular and tubuloin-
terstitial damage [29—32]. In a number of large series of patients
with FSGS, those with nephrotic range proteinuria have had a
more progressive course than patients with subnephrotic protein-
uria [1, 32, 33]. Even among FSGS patients with the nephrotic
syndrome, those with the highest proteinuria have had the most
rapid progression to renal failure [34]. Similarly, in other forms of
primary glomerular disease such as membranous nephropathy
and membranoproliferative glomerulonephritis, heavy protein-
uria constitutes a risk factor for progressive renal damage [35, 36].
At presentation, patients with idiopathic collapsing FSGS arc
more likely to have impaired renal function, manifested by an
elevated serum creatinine, when compared to patients with classic
idiopathic FSGS. An elevated serum creatinine was present in all
the patients reported by Weiss, and 62% of 16 patients described
by Detwiler et al had a serum creatinine at presentation of greater
than 2 mg/dl [9, 10]. While this may, in part, be a consequence of
glomerular collapse and sclerosis, there is also far greater tubu-
lointerstitial damage in these patients. In many glomerular dis-
eases, including a number of studies dealing with FSGS, it is the
severity of the tubulointerstitial damage that correlates best with
the degree of reduction in glomerular filtration rate (GFR) and
the rate of progression to ESRD [36—39]. We found the serum
creatinine at biopsy to correlate significantly and independently
with both the amount of glonieruloselerosis and the degree of
tubular damage in both the collapsing and control FSGS groups
(Table 9). This tubulointerstitial damage may be a consequence of
the glomerular injury through disruption of the post-glomerular
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circulation, tubular protein trafficking with promotion of local
cytokine and growth factor production recruiting inflammatory
infiltrates and promoting fibrogenesis, the formation of large
obstructing casts or other mechanisms. The large echogenic
kidneys found by ultrasound in some patients with collapsing
FSGS likely relate to the tubulointerstitial infiltrates, edema,
fibrosis and dilated tubules as has been documented in HIVAN.
In both idiopathic collapsing FSGS and HIVAN, the decline in
renal function may be too rapid to allow ample time for fibrosis
and contraction of the parenchyma to produce the small shrunken
kidneys typical of other forms of chronic glomerulonephritis.
Idiopathic collapsing FSGS and HIVAN have some striking
similarities. The prevalence of both diseases has increased dra-
matically in the 1980s and review of our prior biopsy material
from 1974 to 1979 does not document cases of either entity
significantly before this decade [31 Both diseases are associated
with a strong black racial predominance, heavy proteinuria and a
very rapid progression to ESRD over months rather than years
[18, 19, 401. This contrasts with classic idiopathic FSGS in which
even nephrotic patients exhibit a mean time to renal failure of at
least 5 to 10 years [33, 34, 37]. Both idiopathic collapsing FSGS
and HIVAN share many histopathologic features, including
global collapse of the glomerular tuft, marked visceral cell swell-
ing and hyperplasia and prominent tubulointerstitial nephritis
with microcyst formation [18, 41]. One of the patients reported by
Weiss developed AIDS and the HIV-1 status of the remaining five
patients was not clearly defined [9]. However, it does not appear
that the patients with collapsing FSGS described by Detwiler et al
were HIV-1 infected and 12 of the 16 patients were seronegative
for HIV-1 infection. Clinically, none of our collapsing FSGS
patients had symptoms suggestive of HIV-1 infection and all 33
who were tested were seronegative for HIV-1, some repeatedly
over several years of follow-up. No patients subsequently devel-
oped signs or symptoms of HIV-1 infection over a mean follow-up
of 32 months. Moreover, no patient was in a high risk group for
HIV-1 infection (such as intravenous drug use, homosexual, etc.).
The tubulo-reticular inclusions (TRI5) commonly found in the
endothelial cells in HIVAN were distinctly absent in 41 cases and
extremely sparse in the remaining two cases, and no biopsy
displayed granular degeneration of nuclear chromatin [18, 41].
Therefore, despite many similarities, idiopathic collapsing FSGS
and HIVAN are distinct entities which can be readily distin-
guished on clinico-pathologic grounds.
The etiology of idiopathic collapsing FSGS remains obscure.
The striking similarities to HIVAN suggest a possible infectious!
viral origin. Although less than ten percent of our patients had any
manifestations of constitutional signs or symptoms of an infec-
tious process, all of the patients described by Weiss et al and some
of those described by Detwiler et al had systemic symptoms such
as malaise and fever which could be manifestations of an occult
viral illness [9, 10]. Transgenic mice produced from an HTV-1
genome deleted of gag and pol develop heavy proteinuria, col-
lapsing glomeruloselerosis, tubulointerstitial damage and rapidly
progressive renal failure [42, 43]. These studies suggest that viral
genes may be capable of producing a sclerosing glomerulopathy
similar to collapsing FSGS in the absence of transmissible HIV-1
infection, possibly through the transactivation of fibrogenic host
genes by viral gene products. Mice made transgenie for other viral
genes also have been shown to develop focal glomeruloselerosis
[44]. The possibility exists of a yet unidentified virus as an etiologic
factor in idiopathic collapsing FSGS. Nevertheless, despite ongo-
ing efforts, no evidence for an infectious etiology of this disease
has yet been identified (Jeffery Kopp, NIH, personal communi-
cation). Other non-infectious potential etiologies may relate to
immunologic or hemodynamic damage to the glomeruli. The
striking collapse of the glomerular capillary loops suggest possible
alterations in intra-capillary hemodynamics with acute vasocon-
striction leading to global glomerular contraction. It is also
possible that acute injury to the visceral epithelial cell alters the
compliance of the glomerular capillary walls, perhaps through
defective podocyte adhesion and foot process interdigitation.
Recently, high levels of a circulating permeability factor have
been identified in the serum of some patients with idiopathic
collapsing FSGS [45].
Prior studies of idiopathic collapsing FSGS have suggested a
rapid course to ESRD. In the study by Weiss et al there was a
mean time of 19 months to ESRD and two patients required
hemodialysis within ten weeks of clinical onset of renal disease [9].
In the study by Detwiler et al, among 14 patients followed for 15
months, five patients (36%) reached dialysis and three had died
from complications of renal failure [10]. Schwartz et al, by
contrast, was unable to document a worse prognosis in a group of
cellular FSGS patients, some of whom had collapsing features [46,
47]. By life table analysis, our control group of classic idiopathic
FSGS patients exhibited a mean time to ESRD of 62.5 months,
analogous to that described for similar populations of FSGS
patients [33—35]. By contrast, our collapsing FSGS patients dem-
onstrated a much more accelerated course to renal failure with a
median time from biopsy to ESRD of only 13 months. Two
patients in the series by Weiss et al were treated with prednisone
which was felt to be "ineffective" [9]. In Detwiler's series, 5 of the
14 patients with follow-up were treated with immunosuppression
[10]. Of four treated with corticosteroids, one experienced a
clinical remission, while the single patient treated with cyclophos-
phamide and corticosteroids did not respond [101. Analysis of the
treatment response in our population is also limited by the
retrospective uncontrolled nature of the treatment regimens.
Nevertheless, in our series, of the 26 patients treated with
corticosteroids for at least two months, there were no complete or
partial remissions. This contrasts with a significantly higher re-
sponse rate for our classic idiopathic FSGS patients, despite the
fact that even these patients' treatment course may not have been
as prolonged or intensive as some current regimens propose to
achieve a high remission rate in idiopathic FSGS [48—50]. Given
the rapid progression to ESRD of idiopathic collapsing FSGS, it
is unlikely a more prolonged course of steroids will be successful.
Clearly, any new treatment regimen for idiopathic collapsing
FSGS must use intensive and rapidly acting agents to prevent
renal failure. While only limited numbers of our patients were
treated with other immunosuppressives, it is of interest that of the
three cyclosporine-treated collapsing FSGS patients, one had a
partial and one had a complete remission of proteinuria. These
results must be viewed cautiously, since there were also 3 spon-
taneous remissions making it impossible to reach any firm con-
clusions about the role of cyclosporine without a controlled trial.
Cyclosporine, though, has been used to treat many steroid resis-
tant patients with classic idiopathic FSGS [51—53]. These studies
document a significant remission rate although relapses are
common after discontinuation of the drug [51]. In addition,
several pediatric patients with typical HIVAN and a collapsing
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pattern of FSGS have achieved complete remissions on cyclospo-
rifle therapy [54]. The actions of cyclosporine in these patients
may be, in part, immunosuppressive and, in part, hemodynamic.
Of interest, four of the original six patients reported by Weiss et
a! received transplants without recurrence of proteinuria in any
patient in up to three years of follow-up [9]. Of our patients, seven
received allografts without documented recurrence to date. This
may relate to the intensive immunosuppression, including cyclo-
sporine, given at the initiation of transplantation.
In our study, certain factors within the group with collapsing
FSGS predicted the progression to renal failure. These included
an elevated serum creatinine at biopsy and lack of a remission of
proteinuria. Whereas, in the control group, we were able to
demonstrate significant correlations of the degree of proteinuria
and glomeruloscierosis to the rate of decline in renal function
(Tables 8 and 10), no equivalent significant correlates could be
found in collapsing FSGS. Though a rare feature, the presence of
segmental collapse in the control FSGS group was a strong
independent predictor of the rate of decline in renal function.
This suggests that our collapsing FSGS group was a more
homogenous group in terms of the degree of proteinuria and the
severity of various histologic features such that we could not
separate out any factors as predictive of the rate of decline in
renal function. In other words, it is the presence of glomerular
collapse and its associated tubulointerstitial changes rather than
their severity which appear to predict poor outcome.
Idiopathic collapsing FSGS is an important subgroup of FSGS
with an increasing frequency over the last two decades. Its
dramatic clinical presentation, rapid progression to renal failure
and poor response to conventional treatment distinguish it clini-
cally from classic idiopathic FSGS. Similarities to HIVAN may
shed light on its pathogenesis and potential therapy. Studies
dealing with the course and therapy of FSGS should control for
patients with the collapsing variant since it clearly has a less
favorable course and greater steroid resistance than classic FSGS.
The optimal therapy for this disease is unknown. In light of our
findings, future studies should consider trials of more intensive
intravenous corticosteroids and other immunosuppressive regi-
mens in an attempt to prevent or impede irreversible renal
damage.
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